

OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
- Robust patent portfolio ([15 patents and patent applications](#))
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
- Significantly undervalued compared to its peers


PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases COVID-19	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Substance Use Disorder Methamphetamine	Phase 2	CTA with University of Wisconsin
Psilocybin	Neurological TBI (Concussion), Stroke	Phase 2	CTA with University of Wisconsin
Psilocybin (Oral Thin Film)	Mental Health Depression, Anxiety	IND-enabling	Target FDA Approval
Cannabidiol CBD	Liver Diseases Autoimmune Hepatitis	Filing IND	Plan for Phase 2

EXPECTED MILESTONES Q2-2022

- ▶ **Apply for FDA EUA Approval for Bucillamine in the treatment of COVID-19**
- ▶ Complete enrollment of Phase 3 COVID-19 study
- ▶ Phase 2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ Phase 2 study - Psilocybin in TBI at University of Wisconsin
- ▶ Psilocybin oral thin film strip scale-up
- ▶ FDA pre-IND for Psilocybin oral thin film strip
- ▶ Rollout clinical program for Psilocybin with University of Antigua

VALUATION COMPARISON



STRATEGIC PARTNERS



TEAM

Management

Michael Frank (Chairman & CEO)
Carmelo Marrelli (CFO)
Derrick Welch (Founder, Psilocin Pharma)

Scientific and Clinical

Dr. Kelly McKee (CSO)
Dr. Osnesmo Mpanju (Regulatory)
Dr. John Fahy, MD (Clinical and Scientific Advisor)
Dr. Joel Moody, MD (Medical and Clinical Advisor)

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

STOCK INFORMATION

Ticker:	CSE: RVV, OTC: RVVTF, FRANKFURT: 31R
Share Price:	\$0.185 (March 31, 2022)
52-week High / Low:	CAD \$0.65 / \$0.175
Shares Outstanding:	318,458,751
Market Cap:	CAD ~ \$60,000,000